Trial Profile
An open-label, non-randomized, multicenter, two-stage, phase 2 study of S-1 in chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2011 Planned End Date changed from 1 Nov 2009 to 1 Oct 2008 as reported by ClinicalTrials.gov.
- 22 Apr 2008 New trial record.